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AbstrACt
Introduction Cellulitis represents a significant burden to 
patients’ quality of life (QOL) and cost to the healthcare 
system, especially due to its recurrent nature. Chronic 
oedema is a strong risk factor for both an initial episode 
of cellulitis and cellulitis recurrence. Expert consensus 
advises compression therapy to prevent cellulitis 
recurrence in individuals with chronic oedema, however, 
there is little supporting evidence. This research aims to 
determine if the management of chronic oedema using 
compression therapy effectively delays the recurrence of 
lower limb cellulitis.
Methods and analysis A randomised controlled trial 
with cross-over will be used to assess the impact of 
compression therapy on clinical outcomes (time to next 
episode of cellulitis, rate of cellulitis-related hospital 
presentations, QOL and leg volume). Using concealed 
allocation, 162 participants will be randomised into the 
intervention (compression) or control (no compression) 
group. Randomisation will be stratified by prophylactic 
antibiotic use. Participants will be followed up at 6 monthly 
intervals for up to 3 years or until 45 episodes of cellulitis 
occur across the cohort. Following an episode of recurrent 
cellulitis, control group participants will cross-over to the 
intervention group. Survival analysis will be undertaken to 
assess the primary outcome measure of time to cellulitis 
recurrence. The hypotheses are that compression therapy 
to control lower limb chronic oedema will delay recurrent 
lower limb cellulitis, reduce the rate of associated 
hospitalisations, minimise affected limb volume and 
improve the QOL of this population.
Ethics and dissemination Ethics approval has been 
obtained from the ethics committees of all relevant 
institutions. Results will be disseminated through 
relevant peer-reviewed journal articles and conference 
presentations.
trial registration number ACTRN12617000412336; Pre-
results. The ICTOC trial is currently in progress. Participant 
recruitment started in May 2017 and is expected to 
continue until December 2019. 
bACkground And rAtIonAlE
Cellulitis is a common acute bacterial infec-
tion of the skin and subcutaneous tissue.1 The 
majority of cellulitis episodes (69%–81%) 
occur in the lower limbs.2–4 In Australia, 
lower limb cellulitis is associated with signif-
icant health costs due to frequent hospital 
admissions and high levels of morbidity. In 
2014–2015, there were 59 466 hospitalisations 
for cellulitis,5 with the average admission 
lasting 4.3 days.6 In 2013–2014, cellulitis was 
the third leading cause of potentially prevent-
able hospital admissions, with over half of 
all admissions for cellulitis being considered 
potentially preventable.6 7 Erysipelas is an 
infection similar to cellulitis, which typically 
affects more superficial tissues. As the terms 
erysipelas and cellulitis are often used inter-
changeably and most clinical studies do not 
differentiate between them, this paper will 
consider them as one entity.
Recurrence of cellulitis is common and 
represents a significant proportion of the 
disease burden. In a 3-year time frame cellu-
litis has been reported to recur in 29%–47% 
of patients,8 9 with a case series in Sweden 
finding that 13% of patients admitted for 
cellulitis developed two or more recurrences 
within 3 years.9 In light of the significant 
recurrence rates, effective interventions 
strengths and limitations of this study
 ► Randomisation of participants will be stratified by 
prophylactic antibiotic use to ensure antibiotic use 
does not confound treatment outcome.
 ► Due to the nature of the intervention, blinding is not 
feasible for participants or assessors.
 ► Assessment tools and methods (perometer, diagno-
sis of cellulitis by medical practitioners external to 
the trial, verification of data using the medical record 
or general practitioner) have been selected to mini-
mise potential measurement bias.
 ► The use of broad inclusion criteria will allow for trial 
results to be generalised to adults across a range of 
settings nationally and internationally.
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which reduce recurrence could limit the disease burden 
and improve patient outcomes.
Oedema occurs when capillary filtration overwhelms 
the available lymphatic drainage.10 Lymphoedema specifi-
cally refers to persistent oedema resulting from lymphatic 
drainage failure.11 Chronic oedema is an umbrella term 
that refers to oedema resulting from insufficient lymphatic 
drainage, where the principal cause of oedema may be 
increased capillary filtration and/or lymphatic drainage 
failure.11 As such, the term chronic oedema encompasses 
oedema of various aetiologies, including lymphoedema. 
For the purpose of this trial, we will use the term chronic 
oedema.
Lymphoedema and chronic oedema are potent risk 
factors for developing lower limb cellulitis and for its 
recurrence.4 8 12 13 It is broadly accepted that the relation-
ship between cellulitis and chronic oedema is a vicious 
cycle.8 14 Chronic oedema predisposes individuals to 
cellulitis and with each episode of cellulitis, the lymphatic 
system is further impaired, increasing residual oedema 
and heightening risk of future cellulitis infections.14 
Thus, chronic oedema is not only a result of cellulitis but 
also increases the risk of recurrence.14
The standard treatment for chronic oedema includes 
compression therapy and skin care.15 Compression 
bandaging can be used to reduce oedema in a limb, and 
daily wear of compression garments is used to control 
oedema. There is general consensus that in addition to 
antibiotic prescription, compression to manage oedema 
should be an adjuvant treatment for patients with chronic 
oedema who are experiencing cellulitis recurrence.1 8 14 16 
Despite this common recommendation and the strong 
evidence supporting the relationship between oedema 
and cellulitis, there is a paucity of evidence to support 
the use of compression to manage chronic oedema to 
prevent cellulitis recurrence.
The time-intensive nature of compression therapy and 
the fact that measuring meaningful outcomes requires 
lengthy assessment periods probably contribute to the 
lack of research in this field. Only one study has been 
conducted on the impact of oedema management on 
cellulitis recurrence,17 with a second study incidentally 
observing a reduction in ‘infection’ among patients 
receiving oedema management, although this was not 
a research objective.18 While both studies support the 
hypothesis that oedema management decreases cellulitis 
recurrence, their conclusions are hampered by meth-
odological limitations, including pre-post intervention 
methods, small sample sizes and change in infection 
rate not being specified a research objective.17 18 While 
research regarding compression therapy to prevent cellu-
litis recurrence is scarce, there is high-quality evidence to 
support the use of prophylactic antibiotics. A multicentre, 
double-blind, randomised controlled trial (RCT) found 
that the use of prophylactic antibiotics in patients experi-
encing recurrent cellulitis is effective in preventing subse-
quent attacks, although the effect diminishes following 
prophylaxis cessation.19 A 2017 Cochrane systematic 
review of interventions to prevent cellulitis identified 
six studies investigating prophylactic antibiotics, but no 
other randomised trials investigating other prophylactic 
measures such as oedema management or skin care.20 
Thus further research into the efficacy of prophylactic 
measures other than antibiotic is warranted.20
The following protocol describes a RCT with cross-over 
to determine if the use of compression therapy for adults 
experiencing lower limb recurrent cellulitis and chronic 
oedema will delay cellulitis recurrence.
rEsEArCh hypothEsEs
The hypotheses are that compression therapy to control 
lower limb chronic oedema will delay recurrent lower 
limb cellulitis, reduce the rate of associated hospitalisa-
tions, minimise affected limb volume and improve the 
quality of life (QOL) of this population.
rEsEArCh objECtIvEs
primary objective
The primary objective was to determine if compression 
therapy delays the recurrence of lower limb cellulitis in 
adults with lower limb chronic oedema and recurrent 
cellulitis.
secondary objectives
The secondary objectives were to determine if, in adults 
with lower limb chronic oedema and recurrent cellulitis, 
compression therapy: (1) reduces the rate of cellulitis-re-
lated hospital presentations; (2) reduces affected leg 
volume; and (3) improves QOL.
trIAl dEsIgn
A RCT with cross-over will be used to assess the impact 
of compression therapy on clinical outcomes (time to 
next episode of cellulitis, rate of cellulitis-related hospital 
presentations, QOL and leg volume). Participants will be 
randomised to the intervention or control group by block 
randomisation using sealed opaque envelopes. As prophy-
lactic antibiotics have been shown to influence cellulitis 
recurrence,19–21 randomisation of participants will be strat-
ified by prophylactic antibiotic use. Following an episode 
of cellulitis, participants in the control group will cross-
over into the intervention group, whereas intervention 
group participants will remain in their original group and 
continue to receive compression therapy. Figure 1 shows 
the proposed participant allocation process.
The absence of high-quality evidence regarding the 
impact of compression therapy on recurrence of cellulitis 
means there is uncertainty as to whether it is an effective 
intervention, justifying the use of an RCT. Although there is 
no high-quality evidence to support the use of the compres-
sion therapy to prevent cellulitis in this patient population, 
it reflects the accepted expert opinion and the standard 
clinical practice of the institution conducting the trial. 
Protected by copyright.
 o
n
 Septem
ber 25, 2019 at University of Canberra S/S250016.
http://bmjopen.bmj.com/
BM
J O
pen: first published as 10.1136/bmjopen-2019-029225 on 15 August 2019. Downloaded from 
3Webb E, et al. BMJ Open 2019;9:e029225. doi:10.1136/bmjopen-2019-029225
Open access
Therefore, the trial design crosses the control group partic-
ipants over into the intervention group following the first 
episode of cellulitis to ensure no participant continues to 
experience recurrent cellulitis episodes without receiving 
the institution’s standard intervention.
MEthods
study setting and population
The trial will be conducted at the Calvary Public Hospital 
Bruce (CPHB) outpatient lymphoedema clinic. Adults 
with lower limb chronic oedema and a history of recurrent 
cellulitis who meet the eligibility criteria will be recruited 
from the two major ACT public hospitals (CPHB and 
Canberra Hospital) and general practitioners servicing 
the ACT and nearby NSW residents.
Eligibility criteria
Inclusion criteria
 ► ≥ 18 years of age.
 ► Two or more episodes of cellulitis diagnosed in the 
same leg in the past 2 years (at the time of referral). 
Clinical diagnosis of cellulitis ideally will have been 
based on the presence of acute erythema, oedema, 
warmth and pain, with spreading involvement of the 
skin and subcutaneous tissues, malaise and possibly 
fever.1 22 23
 ► Chronic oedema (oedema persisting ≥3 months) 
in the leg(s) that have had recurrent cellulitis diag-
nosed (presence of oedema confirmed by an accred-
ited lymphoedema therapist through interview and 
physical examination, including a thorough medical 
history combined with limb palpation and visual 
assessment).
 ► Understanding of involvement in the study as per the 
participant information sheet.
 ► Provision of informed consent.
 ► Able to attend regularly scheduled appointments for 
the duration of the study.
 ► Has a valid Medicare number.
Exclusion criteria
 ► Currently wearing effective compression garments 
(≥compression class 2, or compression class 1 if consid-
ered effective by a lymphoedema therapist) regularly 
(≥5 days per week).
 ► Declines to participate or is unable to participate for 
whatever reason.
 ► Receiving end of life care.
 ► Medically unstable.
 ► Chronic wound/ulcer, or a wound/ulcer requiring 
specialist treatment or treatment that prevents the use 
of compression garments.
 ► Unable to wear compression (unable to don/doff 
garments or has a medical condition that contraindi-
cates the use of compression).
Interventions
All assessments, interventions and outcome measures 
will be conducted by a physiotherapist or occupational 
therapist who meets the registration requirements for 
category one of the Australian National Lymphoedema 
Practitioners Register.24
At the initial appointment, eligibility will be formally 
checked, and those who consent to participate will 
undergo stratified randomisation using sealed, opaque 
and identical envelopes that are sequentially numbered. 
Prior to randomisation, baseline measures including 
number of episodes of cellulitis in the 2 years prior to 
referral, duration of chronic oedema, referral source 
and demographics will be captured. The presence of 
identified potential risk factors for cellulitis will also be 
recorded, including history of tinea or other fungal infec-
tions between toes, diabetes mellitus, obesity and chronic 
venous insufficiency.3 4 12 25 26
At the initial appointment, participants in both the 
control and intervention groups will receive education 
(verbal and written) regarding cellulitis and how to 
decrease the risk of recurrence. Education will include 
the benefits of skin care, prevention of tinea or other 
fungal infections between toes, maintaining healthy body 
weight and regular exercise.
For the intervention group, the initial appointment will 
also be used to plan appropriate compression therapy 
which will be provided at subsequent appointments. 
Compression therapy will involve the application of 
compression garments (compression stockings or wraps) 
and may or may not involve compression bandaging to 
minimise oedema prior to the fitting of compression 
garments. The number of appointments necessary for 
the provision of compression therapy will be individual-
ised to meet participant requirements.
Figure 1 Anticipated participant flow through trial.
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Participants in both groups will be followed for up 
to 3 years at 6 monthly intervals (table 1) to complete 
outcome measures and to continue to receive the allo-
cated treatment (education with or without compres-
sion therapy). At each appointment, the therapist will 
inform each participant of changes in their limb volume, 
providing tangible feedback to support ongoing partici-
pant attendance. Throughout the trial, participants in the 
intervention group may require additional appointments 
for compression therapy (compression bandaging, and 
measure for and provision of compression garments). 
Intervention compliance (number of days per week 
garments are worn) and adverse effects will be captured 
by self-report.
Cross-over of control group participants will be triggered 
on clinician identification of cellulitis. The recurrence 
of cellulitis will be checked at scheduled appointments, 
however, if a participant reports a recurrence between 
scheduled assessments, they will be reviewed at an 
additional appointment to record outcome measures 
(table 1), and to commence cross-over for control group 
participants. Date of cross-over will be defined as the day 
compression garments are initially fitted.
outcome measures
Table 1 shows the timeline for completion of trial activi-
ties and outcome measures.
The primary outcome is ‘observed time to the first 
episode of cellulitis recurrence’. Cellulitis recurrence will 
only be assessed in a leg that has been assessed as having 
chronic oedema, thus if cellulitis occurs in a leg that was 
not previously identified as having chronic oedema, the 
infection will not be considered a recurrence. Cellulitis 
will be diagnosed by medical practitioners external to the 
study. Date of cellulitis recurrence (and associated hospi-
talisation) will be gained by participant self-report and 
may be verified using medical records from the hospitals 
and/or general practitioners.
Secondary outcomes include: (1) rate of cellulitis-re-
lated hospital admissions; (2) percent change in leg 
volume from baseline, measured using the perometer; 
(3) QOL, assessed using the LYMQOL and EuroQol Five 
Dimension Scale (ED-5D-3L). The occurrence of cellu-
litis-related hospital admissions will be measured in the 
same manner as cellulitis recurrence.
Percent change in leg volume will be measured using 
a perometer, an optoelectronic imaging device designed 
to measure limb volume.27 The perometer has excellent 
intra-rater reliability (ICC=1.0; 95% CI: 0.99 to 1.00) and 
inter-rater reliability (ICC=1.0; 95% CI: 0.97 to 1.00), is 
sensitive to changes in limb volume28–30 and is a valid 
measure of knee volume.27 Leg volume will be measured 
between 53 and 400 mm height from the ground using the 
perometer. Monthly calibration of the perometer will be 
conducted using a standardised object of known volume 
(875 mL) to minimise instrument error, ensuring consis-
tency of this measurement device across the duration 
of the trial. Use of this device will also prevent potential 
differential measurement bias arising from lack of thera-
pist blinding.
Where limb volume cannot be measured using the perom-
eter, due to impaired mobility of a participant or equipment 
failure, summated circumferential leg measurements will be 
used following expert clinical guidelines. Circumferential 
leg measures will be taken at the mid foot, oblique ankle and 
at 10, 20, 30 and 40 cm intervals up the leg using a measure-
ment board. Circumferential limb measurement also has 
excellent intra-rater reliability (ICC=0.977–0.996; 95% CI: 
0.960 to 0.998) and inter-rater reliability (ICC=0.942–0.994; 
95% CI: 0.936 to 0.997).31
QOL will be measured using LYMQOL, a validated, 
condition-specific QOL tool for people with lower limb 
lymphoedema,32 and the EQ-5D-3L, a generic prefer-
ence-based measure of health-related QOL that comprises 
five dimensions of health.33 The EQ-5D can be used to 
calculate quality-adjusted life years for the purpose of 
economic evaluation.33 A systematic review has found the 
EQ-5D has good validity and responsiveness for people 
with skin diseases, although the tool has not been specif-
ically validated within a population suffering cellulitis.33
Exploratory analysis will be conducted to test the 
robustness of the trial hypotheses and may include assess-
ment of cellulitis recurrence post cross-over, intervention 
compliance, participant demographics, risk factors and 
per protocol analysis.
sample size and duration of follow-up
The sample size has been calculated for the primary 
objective of detecting a difference in time to cellulitis 
recurrence between the control and intervention groups. 
The sample size estimation is based on the assumptions 
that the 3-year cellulitis recurrence rate in control partic-
ipants is approximately 47%8 and compression therapy 
will reduce the 3-year incidence of recurrent cellulitis by 
50%.17 18 Assuming that events occur at a constant rate, 
these assumptions correspond to a hazard ratio (HR) of 
0.42. The eligibility criteria of two or more episodes of 
cellulitis in the same leg in the past 2 years has been used 
so that the trial cohort have an increased likelihood of 
cellulitis reoccurring during the follow-up period.
It is assumed that patients will be recruited over a 
2.5 year period, and the total study duration will be 3.5 
years. Length of participant follow-up will vary based on 
time of enrolment. Using a sequential design software 
package gsDesign in R,34 in order to detect a HR of 0.42 
with 80% power and 2.5% (one-sided) type 1 error, a 
total of 45 cellulitis recurrences are needed. Under the 
present recruitment and recurrence assumptions, we 
plan to recruit 162 participants (81 per arm).
An interim analysis will be performed by a Data 
Monitoring Committee after 23 episodes of cellulitis. 
A log-rank test will be used to assess group differences. 
If a nominal (one sided) significance level of p=0.003 
is detected, indicating a strong clinical effect, the study 
will be ceased. If the Data Monitoring Committee recom-
mends that the study continue to 45 episodes of cellulitis, 
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the final analysis will use a log-rank test with (one-sided) 
significance level p=0.0238. These efficacy bounds were 
derived using a Hwang-Shih-DeCani spending function 
with gamma = −4 to preserve an overall type 1 error rate 
of 5%.
recruitment and enrolment of participants
Recruitment will be conducted over a 2.5-year period. A 
multifaceted recruitment strategy will be used. In order 
to capture acute patients (seen in CPHB and Canberra 
Hospital emergency departments and wards), all patients 
diagnosed with lower limb cellulitis during their hospital 
presentation will be sent information regarding the trial 
and how to contact the CPHB lymphoedema service if 
they would like to learn more information or self-refer. 
To recruit from the community, the study will be adver-
tised via posters, radio and articles in various magazines 
and newspapers, providing information about the trial 
and encouraging self-referral. Education (in-services, 
faxes, newsletters and posters) and referral forms will be 
provided to recruitment sites (Canberra Hospital, CPHB, 
General Practices within the surrounding region) to 
encourage health professionals to refer patients. Patients 
from these sites must consent to a referral to the CPHB 
lymphoedema service for the study, but do not need to 
consent to participate in the trial at the time of referral.
After self-referral, a screening phone call will be 
conducted to check inclusion/exclusion criteria, and for 
those who appear to be eligible, an appointment at the 
service will be made with a lymphoedema therapist. At 
this appointment, candidates will be provided with partic-
ipant information and consent forms, a verbal explana-
tion of the study and an opportunity to ask questions, 
prior to choosing to consent or decline to participate.
To promote participation in the study, a free set of 
compression garments will be offered by a secondary 
sponsor. Compression garments are expensive, which can 
provide a barrier to treatment compliance. Participants 
in the intervention group will receive the free garments at 
intervention commencement. Participants in the control 
group will receive the free garments following their first 
cellulitis recurrence (cross-over) or on study completion 
for those who do not experience recurrence.
patient and public involvement
A patient-centred approach was used to design this study. 
The trial design replicates the institution’s standard clin-
ical practice as closely as possible, while aiming to mini-
mise any additional burden to participants. Patients from 
the participating clinical service were surveyed to assess 
acceptability of the model of care undertaken by the 
trial. As the time required to attend appointments was 
identified as a potential burden, the trial was designed 
to minimise scheduled follow-up appointments. Cost of 
compression therapy was identified as a likely financial 
burden which is minimised through the provision of two 
sets of free compression garments and use of accessible 
funding schemes. Referral processes were developed to 
enable patients to self-refer to the trial. The cross-over 
design feature was chosen to ensure participants do not 
continue to experience episodes of recurrent cellulitis 
without receiving the institution’s standard intervention.
Assignment of interventions and blinding
Participants will be assigned to the intervention or control 
group in a 1:1 allocation ratio using block randomisation, 
with a block size of 10. Sealed sequentially numbered 
opaque envelopes will be used to ensure concealed 
allocation. A computer-generated allocation sequence 
will be created and supplied by a consultant statistician 
and saved in a folder only accessible by administration 
staff. Administration staff will prepare the sealed sequen-
tially numbered opaque envelopes, ensuring therapists 
involved in participant allocation have no premature 
access to the letters.
Therapists will not be blinded due to the practicalities 
of providing the intervention within a small team of four 
specialised clinicians. Further, the visible nature of the 
treatment and lack of feasible sham interventions prevent 
effective blinding of both assessors and participants. 
Additionally, for ethical reasons, participants will be fully 
informed of both the potential interventions, prior to 
consenting to participate.
data management and quality assurance
Prior to any involvement in the trial, therapists will receive 
training regarding trial implementation and completion 
of outcome measures. Refresher training will be provided 
to therapists annually and the trial protocol will be kept 
readily available.
For the duration of the study, data will be stored in iden-
tifiable form in both a locked office and on a secure access 
hard drive, accessible only by designated research staff. 
Data will be entered by a research officer or members of 
the research team. For quality assurance, data complete-
ness will be reviewed annually, and all entered data will be 
cross-checked against written records at least once after 
initial entry. Following trial conclusion and prior to data 
analysis, all data will be de-identified. Data will be stored 
for a minimum of 7 years as per CPHB policy, however data 
may be retained for longer for identified new, ethically 
approved ancillary studies. A contract with the secondary 
sponsor ensures that they will have no involvement in the 
study design, in the collection, analysis, or interpretation 
of data, in the writing of the manuscript or in the decision 
to submit the manuscript for publication.
participant retention
Once a participant is enrolled in the study, every effort 
will be made to ensure they are followed up as per the 
protocol. Where participants cannot attend a scheduled 
appointment, a phone call assessment may be completed 
to gain the primary outcome measure. Phone call assess-
ment will not allow for completion of limb volume or QOL 
measures but will capture the date of cellulitis recurrence 
and cellulitis-related hospitalisation.
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Participants can withdraw from the study at any point. 
For participants who withdraw, the medical record and/
or general practitioner report may be checked according 
to the schedule for cellulitis recurrence and cellulitis-re-
lated hospitalisation.
termination criteria
Participants will be withdrawn from the study in the 
case of death, withdrawal of consent or if they develop a 
wound or lymphorrhoea requiring compression for effec-
tive management.35
proposed methods for data analysis
For the main outcome measure of ‘time to the first 
episode of recurrent cellulitis’, survival analysis will be 
undertaken. Kaplan-Meier plots will be used to visualise 
patterns of time to first cellulitis recurrence between the 
groups, with a log-rank test being used to determine if 
there is a statistically significant difference between the 
groups. Cox proportional hazards regression may also be 
used to adjust for important risk factors. Right censoring 
will be used for participants who are lost to follow-up. 
Intention to treat analysis will be used, with all enrolled 
participants being assessed according to their randomisa-
tion, regardless of protocol adherence.
For the secondary outcomes of percent change in limb 
volume and QOL, measures will be taken at multiple time 
points. Therefore, groups will be compared using a linear-
mixed model or using a repeated measures analysis. A 
generalised linear model will be used to assess the rate of 
cellulitis-related hospital admissions.
MInIMIsIng bIAs
selection and attrition bias
Use of randomisation will minimise selection bias and 
confounding. Stratification will ensure that the use of 
prophylactic antibiotics is not confounded with treat-
ment assignment. The presence and distribution of other 
known potential confounding factors will be measured 
and reported. Intention to treat analysis will be used 
to prevent attrition bias that may occur through loss to 
follow-up of participants.
Internal validity
Use of an RCT and validated measurement tools support 
the internal validity of this research. The lack of blinding 
of therapists and participants has the potential to induce 
surveillance and recall bias and lead to differential 
measurement error in the reporting of cellulitis recur-
rence. To minimise this, the accuracy of self-report of 
recurrence may be cross-checked with the participant’s 
general practitioner or medical record (from CPHB and 
Canberra Hospital). Diagnosis of cellulitis by doctors 
external to the study and use of perometry to measure 
limb volume will reduce the risk of measurement bias and 
thus differential measurement error. Calibration of the 
perometer will be performed to prevent non-differential 
measurement error that could result from machine error.
Control and intervention group participants have the 
same appointment schedule throughout the duration of 
the trial, however participants in the intervention group 
may attend more appointments than the control group. 
This systematic difference in clinician contact could influ-
ence the participant’s perceived benefit, allowing poten-
tial bias in self-reported measures (LYMQOL, EQ-5D).
Participants enrolled in the trial have a history of two or 
more episodes of cellulitis diagnosed by medical practi-
tioners independent to the trial. As misdiagnosis of lower 
limb cellulitis is not uncommon,36 the trial may include 
incorrectly diagnosed participants leading to non-differ-
ential misclassification.
AnAlysIs of Costs
A within-trial cost-analysis assessment will be conducted. 
Data obtained from the trial and participant medical 
records will be used to assess the cost of oedema manage-
ment and the cost of an episode of cellulitis from both an 
individual and a health systems perspective. On comple-
tion of the RCT, the cost-effectiveness and cost-utility of 
chronic oedema management to prevent recurrent cellu-
litis may be assessed.
EthICs And dIssEMInAtIon
Ethics approval has been granted for these studies by 
three institutional committees:
1. Calvary Public Hospital Bruce Human Research Ethics 
Committee (53-2016).
2. Australian Capital Territory Health Human Research 
Ethics Committee (ETH.4.17.092).
3. University of Canberra Human Research Ethics 
Committee (cross-institutional approval).
Regardless of the outcome of the trial, the findings 
are planned to be submitted for publication in rele-
vant peer-reviewed journals and for presentations at 
national and international conferences. Key findings will 
be disseminated to identified stakeholders, including 
primary contact clinicians for patients experiencing 
cellulitis (doctors and health professionals in acute and 
community settings), clinicians who manage chronic 
oedema and professionals who may be involved in devel-
oping relevant policy and practice. On request, partici-
pants will be provided with a copy of the trial results.
dIsCussIon
Although current expert consensus recommends 
compression therapy to prevent the recurrence of cellu-
litis in patients with lower limb chronic oedema, the 
evidence supporting this recommendation is lacking. This 
study aims to review the efficacy of compression therapy 
to allow for better-informed practice and policy. Given the 
high incidence of cellulitis within Australia and around 
the world, reducing cellulitis recurrence will significantly 
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decrease the cost to the healthcare system and reduce 
the financial and personal burden of sufferers. Further, 
should compression therapy reduce the recurrence of 
cellulitis, this may limit the dependence and widespread 
prescription of prophylactic antibiotics. This trial will be 
performed on adults receiving healthcare services in the 
Australian Capital Territory, however, the results will be 
relevant to cellulitis management throughout Australia 
and internationally.
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